Archive · 5 Dec 2025
Dr. Reddy's Wins Court Ruling on Semaglutide
Dr. Reddy's Laboratories won a court case against Novo Nordisk about a drug called Semaglutide.
The court said Dr. Reddy's can make and sell this drug in countries where Novo Nordisk doesn't have a patent.
Semaglutide is used to treat diabetes and help with weight loss.
Novo Nordisk tried to stop Dr. Reddy's, but the court said they didn't have a strong enough case.
Dr. Reddy's is happy because they can now make the drug more affordable for people.
Dr. Reddy's Laboratories won a court ruling against Novo Nordisk over the drug Semaglutide.
The Delhi High Court allowed Dr. Reddy's to manufacture and export Semaglutide to countries where Novo Nordisk lacks patent protection.
Semaglutide is used to treat type 2 diabetes and for chronic weight management.
Novo Nordisk failed to prove a strong enough case for an interim injunction.
Dr. Reddy's can now produce the drug, making it more accessible and affordable.
- Who
- Dr. Reddy's Laboratories and Novo Nordisk
- What
- Court ruling on Semaglutide drug patent
- When
- December 5, 2025
- Where
- Delhi High Court, India
- Why
- To resolve a legal dispute over the manufacturing and export of Semaglutide
- Company
- Dr. Reddy's Laboratories
- Drug
- Semaglutide
- Opponent
- Novo Nordisk
- Court
- Delhi High Court
- Ruling Date
- December 5, 2025
- Drug Use
- Type 2 diabetes and chronic weight management